Drug Device Combination Market Segmentation:
The drug device combination market is segmented based on product, application, end user and region.
Based on product, the market is segmented into catheter, advanced wound care products, and others. The catheter segment is sub-segmented into antimicrobial catheter, urological catheters, cardiovascular catheters, oximetry catheters, thermodilution catheters, wound drainage catheter, and others. The advanced wound care products segment is sub-divided into antibiotic wound care, bone graft substitutes, antibiotic bone cements, drug eluting stents, photodynamic therapy. The bone graft substitutes segment is sub-segmented into ceramic based bone graft substitute, allograft-based bone graft substitutes, cell-based bone graft substitutes, and others.
On the basis of application, the market is devised into coronary angioplasty, tachycardia management, non-cardiovascular treatments, peripheral arterial disease (pad), bone treatment, antimicrobial applications, wound care, ophthalmic treatment, and others.
By end user, the drug device combination market is divided into hospitals & clinics, ambulatory centres, and academic & research organization, and others. In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely- the Americas, Europe, Asia-Pacific and the Middle East & African region.
Regional Market Summary
The Americas dominated the drug device combination market owing to rising prevalence of cardiovascular diseases and presence of major market players within the region. Additionally, suitable reimbursement policies, high healthcare expenditure, and developed healthcare sector in the U.S. and Canada boost the market to grow. In 2017, it was estimated that Europe stood second in the global drug device combination owing to the to the presence of a well-developed healthcare infrastructure, increasing awareness for the devices within the region and presence of developed economies within the region. Additionally, a large patient pool boosts the drug device combination market.
Asia Pacific was projected to be the fastest growing region in 2021. This can be attributed due to the increasing penetration of the market players within the region, growing healthcare sector and increasing government support for foreign investments.
On the other hand, the Middle East and Africa held least share in the Global Drug Device Combination Market due to the presence of poor economies and low per capita income, especially within the African region. The Middle Eastern region is estimated to be a major market for the Middle East and African region. This can be attributed due to increasing government funding in the healthcare followed by the presence of developed economies like United Arab Emirates, Saudi Arabia, Dubai, and others within the regional boundaries of the region.
Drug Device Combination Market Key players:
Some of the key players in the drug device combination market are 3M, Abbott Laboratories, AlloSource, Biomet Orthopedics, Inc., Biometrix Medical, Biotronik, Boston Scientific Corporation, C.R. BARD, Inc., Cook Critical Care, Inc., Covidien Ltd, Smith & Nephew Plc, St. Jude Medical Inc, Stryker Corporation, Wright Medical Group, Inc., Zimmer Holding, Inc., and others.
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical trends and current drug device combination market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the drug device combination. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.
Drug Device Combination Market, by Product:
Global Drug Device Combination Market, by Application:
Global Drug Device Combination Market, by End User
Drug Device Combination Market has a growth opportunity with an USD 251.90 Billion by 2030 at 7.2% CAGR.
Drug Device Combination Market has players like AlloSource, 3M, Abbott Laboratories, Biometrix Medical, Biotronik, C.R. BARD, Boston Scientific Corporation, Biomet Orthopedics, Inc., Inc., Covidien Ltd, Cook Critical Care, Inc., St. Jude Medical Inc, Smith & Nephew Plc, Zimmer Holding, Inc., Stryker Corporation, Wright Medical Group, Inc., and others.
Asia Pacific regional Drug Device Combination Market would be the fastest-growing among all the regions.
Americas would dominate the global Drug Device Combination Market.
Drug Device Combination Market would be triggered by end users like academic & research organizations, ambulatory centers, hospitals & clinics, and others.